Skip to main content

Table 1 Outcome measures

From: The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol

Outcome Measurement of variable (units) Statistical estimates and measurement of association of this outcome
Menstrual regulation Number of girls achieved regular menses Rate ratio
Number of cycles per year Mean difference ± SD
Hirsutism Ferriman Gallawey score Mean difference ± SD
Acne scores Lesion counting or grading Standardized mean difference ± SD
Dysglycaemia The rate of occurrence of T2DM, impaired glucose tolerance, and impaired fasting glucose assessed by oral glucose tolerance test and/or fasting blood glucose, and/or HBA1c Rate ratio
BMI kg/m2 Mean difference ± SD
Total testosterone level ng/ml Mean difference ± SD
Total cholesterol mg/dl Mean difference ± SD
LDL mg/dl Mean difference ± SD
HDL mg/dl Mean difference ± SD
Triglyceride mg/dl Mean difference ± SD
Adverse events Number of girls developed: OR, rate ratio
1- GI: all GI related adverse events:
 • Nausea
 • Vomiting
 • Diarrhea
 • Constipation
 • Abdominal pain
 • Flatulence
 • Gastritis
 • GI bleeding
2- thrombosis: all vascular events related to thrombus formation such as:
 • Deep venous thrombosis
 • Stroke
 • Myocardial infarction
 • Pulmonary embolism
3- serious: adverse events that are of major morbidity such as:
 • Any bleeding not including GI bleed
 • Lactic acidosis
 • Liver failure
 • Renal failure
 • Vasculitis
 • Electrolyte imbalance
 • Agranulocytosis
 • Photosensitivity
 • Hypertension
 • Pancreatitis
 • Anaphylaxis
 • Chorea
 • Depression
4- minor: adverse events that are of minor morbidity such as:
 • Headache
 • Fatigue
 • Beast tenderness
 • Vaginal bleeding (spotting)
 • Edema
 • Weight gain
 • Metallic taste
 • Muscle cramp
 • Rash
 • Fever
 • Hot flashes
 • Glucose intolerance
 • Infection
  1. OR odds ratio, T2DM type 2 diabetes mellitus, BMI body mass index, LDL low-density lipoprotein, HDL high-density lipoprotein, GI gastrointestinal